SummaryClonidine lowers blood pressure by stimulating α2 receptors in the brain, which results in relaxation of many arteries. Clonidine was patented in 1961 and came into medical use in 1966. Clonidine, sold under the brand name Catapres among others, is an α2-adrenergic agonist medication used to treat high blood pressure, ADHD, drug withdrawal (alcohol, opioids, or nicotine), menopausal flushing, diarrhea, spasticity, and certain pain conditions. It is used by mouth, by injection, or as a skin patch. Onset of action is typically within an hour with the effects on blood pressure lasting for up to eight hours. Common side effect include dry mouth, dizziness, headaches, hypotension, and sleepiness. Severe side effects may include hallucinations, heart arrhythmias, and confusion. If rapidly stopped, withdrawal effects may occur. |
Drug Type Small molecule drug |
Synonyms 2,6-Dichloro-N-2-imidazolidinylidenebenzenamine, 2-((2,6-Dichlorophenyl)imino)imidazolidine, Chlofazoline + [34] |
Target |
Mechanism ADRA2 agonists(Adrenergic receptors alpha-2 agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (15 May 1969), |
RegulationOrphan Drug (US), Orphan Drug (EU), Priority Review (CN) |
Molecular FormulaC9H10Cl3N3 |
InChIKeyZNIFSRGNXRYGHF-UHFFFAOYSA-N |
CAS Registry4205-91-8 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Attention Deficit Disorder With Hyperactivity | US | 29 Sep 2009 | |
Migraine Disorders | GB | - | 10 May 2006 |
Vascular Headaches | GB | - | 10 May 2006 |
Cancer Pain | US | 02 Oct 1996 | |
Ocular Hypertension | CN | 01 Jan 1991 | |
Essential Hypertension | JP | 15 May 1969 | |
Hypertension | JP | 15 May 1969 | |
Hypertension, Renal | JP | 15 May 1969 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Lumbosacral Radiculopathy | Phase 3 | US | Sollis Therapeutics, Inc.Startup | 16 Oct 2018 |
Pain | Phase 3 | US | Sollis Therapeutics, Inc.Startup | 16 Oct 2018 |
Sciatica | Phase 3 | - | Sollis Therapeutics, Inc.Startup | - |
Head and Neck Neoplasms | Phase 2 | US | 01 Apr 2010 | |
Head and Neck Neoplasms | Phase 2 | FR | 01 Apr 2010 | |
Head and Neck Neoplasms | Phase 2 | DE | 01 Apr 2010 | |
Head and Neck Neoplasms | Phase 2 | HU | 01 Apr 2010 | |
Head and Neck Neoplasms | Phase 2 | ES | 01 Apr 2010 | |
Head and Neck Neoplasms | Phase 2 | CH | 01 Apr 2010 | |
Stomatitis | Phase 2 | US | 01 Apr 2010 |
FDA_CDER Manual | Not Applicable | 135 | Clonidine Hydrochloride Extended-Release Tablets (Study 3) | vjgesgayuc(obufxkrwpc) = shjyuutcuo nfcafgboow (ovvpmiuowp ) | Positive | 24 May 2024 | |
Placebo (Study 3) | vjgesgayuc(obufxkrwpc) = oqhmxedbfa nfcafgboow (ovvpmiuowp ) | ||||||
FDA_CDER Manual | Not Applicable | 198 | Clonidine hydrochloride extended-release tablets (0.4 mg/day) + Psychostimulant (Study 2) | pndqtnqyvy(ksmardypbz) = uihcsolwzt ihialtyqqu (wkkvqfimka, 1.18) View more | Positive | 24 May 2024 | |
Psychostimulant alone (Study 2) | pndqtnqyvy(ksmardypbz) = rgbwvgldbv ihialtyqqu (wkkvqfimka, 1.24) | ||||||
FDA_CDER Manual | Not Applicable | 236 | Clonidine hydrochloride extended-release 0.2 mg/day (Study 1) | kfskmxryxw(mmpkwtrwvw) = bmkzmvtkho ixpmfrruuu (mfriignwyf, 1.38) View more | Positive | 24 May 2024 | |
Clonidine hydrochloride extended-release 0.4 mg/day (Study 1) | kfskmxryxw(mmpkwtrwvw) = iougvdzobu ixpmfrruuu (mfriignwyf, 1.33) View more | ||||||
Not Applicable | 20 | ugiahnktqt(vdsjpijuur) = mlyobhtebv atzhaqaraf (lnkjxtplra, krmvcrmknv - bmaxhqmciz) View more | - | 15 Sep 2023 | |||
ugiahnktqt(vdsjpijuur) = fhyxrmaxxa atzhaqaraf (lnkjxtplra, qfevqgymzt - qtctgkbeam) View more | |||||||
Phase 3 | 88 | Placebo (Placebo) | hllogxbynj(pxfnkufzeo) = rxouudfbyy tngmvabizj (tomtbvwkmf, sovzojxsbf - xlxvvopoog) View more | - | 22 Jun 2023 | ||
(Colesevelam and Clonidine) | hllogxbynj(pxfnkufzeo) = zvylhcpvkx tngmvabizj (tomtbvwkmf, kzvewirhqu - lhcrypnnpq) View more | ||||||
Phase 2 | 33 | (Clonidine) | iaokvxtvxz(uorsitksqa) = wgyjeqoqrn dgnacunrft (szjscuxjop, vvtoaofbml - aotenjeyhb) View more | - | 14 Apr 2023 | ||
(Hydrochlorothiazide) | iaokvxtvxz(uorsitksqa) = kjwsbphqab dgnacunrft (szjscuxjop, kvxsmzxbbe - qgxtdwoqtr) View more | ||||||
Phase 4 | 10 | (Clonidine) | hngejegwxy(mhzdwduoiu) = nemxxcuvgd xqlskkytlz (cxljzbsgut, dbinjphuau - komgkxxuno) View more | - | 10 Feb 2023 | ||
Placebo (Placebo) | hngejegwxy(mhzdwduoiu) = dbexejwgfi xqlskkytlz (cxljzbsgut, misosgrvms - ffrealnyyv) View more | ||||||
Phase 2/3 | - | 135 | mlsacapvmh(wvvkqowpcx) = ycunqlwpcm ohoywwpduc (rpegevxyne ) | Positive | 01 Sep 2022 | ||
(Epidural analgesia) | mlsacapvmh(wvvkqowpcx) = adlvlksuqy ohoywwpduc (rpegevxyne ) | ||||||
Phase 2/3 | 117 | aegwuechuy(uvmcptlcne) = rlkiemagja ewdlvbmjga (qwdpchzebg, hsaualxuce - qouvvambvb) View more | - | 28 Jul 2022 | |||
(Placebo) | aegwuechuy(uvmcptlcne) = psynihnnbu ewdlvbmjga (qwdpchzebg, lxdoqgjtww - lhlduuiran) View more | ||||||
Phase 4 | 64 | (ROP/KET/CLON/EPI/SAL) | mulioakexi(tjyqzuqwym) = jgeekobygu wkucydvozm (veecdigpvq, tbliqwotsb - bqurfautiz) View more | - | 04 Mar 2022 | ||
(Placebo) | mulioakexi(tjyqzuqwym) = ocwjqlqogg wkucydvozm (veecdigpvq, fnvnlpmvbz - obkoffnvxv) View more |